Imagine uncovering the very root cause of vascular cognitive impairment (VCI), a leading contributor to dementia after Alzheimer’s — and doing so opens doors to revolutionary treatment possibilities. But here's where it gets controversial: recent research from the Feinstein Institutes suggests that a fundamental neurochemical imbalance, rather than traditional suspects like oxidative stress or inflammation, might be the primary culprit in microvascular damage linked to VCI. This fresh perspective could forever change how we approach prevention and therapy.
Researchers at Northwell Health’s Feinstein Institutes for Medical Research have made a groundbreaking discovery by identifying a key mechanism behind VCI, which is the second most common form of dementia worldwide. Their recent study, published in the journal Alzheimer’s & Dementia, reveals that dysregulation of vasoactive neuropeptides—specialized molecules that control blood vessel relaxation and constriction—serves as the root trigger for microvascular dysfunction in VCI. This insight not only clarifies what initiates this form of cognitive decline but also points to promising new paths for both drug-based and lifestyle interventions.
Led by Dr. Chunyan Li, an associate professor at the Institute of Bioelectronic Medicine, along with PhD student Willians Tambo from the Elmezzi Graduate School of Molecular Medicine, the team investigated molecular changes through detailed profiling and behavioral experiments using animal models that mimic chronic cerebral hypoperfusion (CCH)—a condition characterized by prolonged reduced blood flow in the brain, which closely resembles what many VCI patients endure. They tested two innovative strategies: administering calcitonin gene-related peptide (CGRP), a molecule known for its potent vessel-widening effects, and activating the body's natural diving reflex, an oxygen-saving mechanism that conserves blood flow.
Both approaches proved highly effective. They restored proper neuropeptide signaling, prevented ongoing narrowing of the tiny blood vessels in the brain, and significantly improved memory and learning skills in their animal subjects. As Dr. Li states, “Vascular cognitive impairment is a devastating condition that currently lacks effective treatments. Our discovery that neuropeptide imbalance is the key driver offers a clear starting point for developing targeted therapies to halt or even reverse the disease process.”
This research challenges previous theories that primarily linked VCI to oxidative stress and inflammation as initial causes. Instead, it suggests that impaired control of blood vessel tone, driven by neuropeptide dysregulation, occurs first, setting off a cascade leading to amyloid buildup and tissue damage—two hallmarks of cognitive decline. Interestingly, this shifts the focus: oxidative stress and inflammation could be consequences that manifest later, rather than the root triggers.
Building on these insights, Dr. Li’s team is advancing a novel, non-invasive therapy: trigeminal nerve stimulation aimed at activating the diving reflex. Supported by the U.S. Department of Defense and winning the 2023 Northwell Health Innovation Challenge, this approach is currently being tested in models of traumatic brain injury and ischemic stroke, both of which increase VCI risk.
Kevin J. Tracey, MD, President and CEO of the Feinstein Institutes, emphasizes the significance: “Understanding how VCI begins is critical because it paves the way for the next generation of precise, targeted treatments. Dr. Li’s work marks a crucial first step in transforming our approach from merely managing symptoms to attacking the disease at its source.”
In essence, these findings not only challenge the conventional wisdom about the origins of vascular dementia but also set a promising trajectory towards developing first-ever interventions aimed at restoring microvascular health and safeguarding cognitive function. As science continues to unravel these mechanisms, the question remains—could this be the breakthrough that finally alters the course of dementia? And what does this mean for the future of neurovascular health? We invite you to share your thoughts—do you agree with this new perspective, or do you see potential flaws? The conversation around brain health is just beginning.
